MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Motif Bio PLC Company Profile (LON:MTFB)

Consensus Ratings for Motif Bio PLC (LON:MTFB) (?)
Ratings Breakdown: 1 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: GBX 112.67

Analysts' Ratings History for Motif Bio PLC (LON:MTFB)
Show:
DateFirmActionRatingPrice TargetActions
6/1/2016Northland SecuritiesReiterated RatingBuyGBX 114View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/21/2016Beaufort SecuritiesReiterated RatingSpeculative BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/11/2015Northland Capital PartnersReiterated RatingBuyGBX 114View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/28/2014 forward)
Earnings History for Motif Bio PLC (LON:MTFB)
No earnings announcements for this company have been tracked by MarketBeat.com

Earnings Estimates for Motif Bio PLC (LON:MTFB)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Motif Bio PLC (LON:MTFB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Motif Bio PLC (LON:MTFB)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
10/5/2015Stakes III,John WilburInsiderBuy100,000GBX 60£60,000Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Motif Bio PLC (LON:MTFB)
DateHeadline
06/24/16 05:15 PMToday Motif Bio PLC Stock Rises - Press Telegraph
06/24/16 07:55 AMMotif Bio (LON:MTFB) Broker Updates - Fiscal Standard
06/23/16 07:59 AMFloats shine light on Amphion's portfolio - Proactive Investors UK
06/12/16 05:12 PMWincanton keeps on trucking
06/07/16 05:31 PMThree small cap drugs stocks to watch for Phase 3 success
06/02/16 08:13 AMMotif Bio PLC's (MTFB) “Buy” Rating Reaffirmed at Northland Securities - Let Me Know About This - Motif Bio PLC's (MTFB) “Buy” Rating Reaffirmed at Northland SecuritiesLet Me Know About ThisMotif Bio PLC logo Motif Bio PLC (LON:MTFB)'s stock had its “buy” rating reaffirmed by analysts at Northland Securities in a research report issued to clients and investors on Wednesday, StockTargetPrices.com reports. They currently have a GBX 114 ($1 ...Analysts Consensus For Motif Bio (LON:MTFB)Risers & Fallersall 2 news articles »
06/01/16 05:48 PMProactive news highlights: Deltex Medical, e-Therapeutics, Motif Bio, Sula Iron and more... - Proactive Investors UK - Proactive Investors UKProactive news highlights: Deltex Medical, e-Therapeutics, Motif Bio, Sula Iron and more...Proactive Investors UKOver at Motif Bio Plc (LON:MTFB), CEO Graham Lumsden has been invited to present at the BIO 2016 convention in San Francisco. The presentation will provide information on the progress of its clinical lead antibiotic, iclaprim, into pivotal phase III ...and more »
06/01/16 05:48 PMRisers & fallers: CityFibre, BMR, LondonMetric, Regal Petroleum - Proactive Investors UK - Proactive Investors UKRisers & fallers: CityFibre, BMR, LondonMetric, Regal PetroleumProactive Investors UKGoldbridges Global Resources PLC (LON:GBGR), up 5.9%. The company said it is confident it is on track to delivering annual gold production of 100,000 ounces by 2019. Motif Bio Plc (LON:MTFB), up 5.0%. The clinical stage biopharmaceutical company ...and more »
06/01/16 08:12 AMEurozone data and falling oil prices dent FTSE 100 Index - Proactive Investors UK - Proactive Investors UKEurozone data and falling oil prices dent FTSE 100 IndexProactive Investors UKScancell Holdings Plc (LON:SCLP) perked up 10.4% to 18.62p as broker Panmure Gordon reiterated its 'buy' rating, while Motif Bio Plc (LON:MTFB) was also benefiting from positive sentiment towards the sector – up 7.4% at 51p. While small-cap indices ...and more »
06/01/16 08:12 AMBlue-chip shares slide while Aim stocks thrive - Proactive Investors UK - Proactive Investors UKBlue-chip shares slide while Aim stocks thriveProactive Investors UKScancell Holdings Plc (LON:SCLP) perked up 10.4% to 18.62p as broker Panmure Gordon reiterated its 'buy' rating, while Motif Bio Plc (LON:MTFB) was also benefiting from positive sentiment towards the sector – up 7.4% at 51p. While small-cap indices ...and more »
06/01/16 08:12 AMWhat's Next for Motif Bio PLC After Today's Huge Increase? - HNN - DirectorsTalk InterviewsWhat's Next for Motif Bio PLC After Today's Huge Increase?HNNThe stock of Motif Bio PLC (LON:MTFB) is a huge mover today! The stock increased 7.37% or GBX 3.5 on May 31, hitting GBX 51. About 289,565 shares traded hands or 20.60% up from the average. Motif Bio PLC (LON:MTFB) has declined 14.77% since ...Motif Bio PLC CEO to Present at BIO 2016DirectorsTalk InterviewsRisers & fallers: Strategic Minerals, Goldbridges, Motif Bio, Starcom, Halfords, WolseleyProactive Investors UKall 3 news articles »
05/31/16 05:33 PMThe FTSE 100 Index trod water as traders shrugged off mixed economic data from the continent - Proactive Investors UK - Proactive Investors UKThe FTSE 100 Index trod water as traders shrugged off mixed economic data from the continentProactive Investors UKScancell Holdings Plc (LON:SCLP) perked up 10.4% to 18.62p as broker Panmure Gordon reiterated its 'buy' rating, while Motif Bio Plc (LON:MTFB) was also benefiting from positive sentiment towards the sector – up 7.4% at 51p. While small-cap indices ...and more »
05/31/16 05:33 PMSmall-cap pharma stocks rise but FTSE 100 Index treads water - Proactive Investors UK - Proactive Investors UKSmall-cap pharma stocks rise but FTSE 100 Index treads waterProactive Investors UKScancell Holdings Plc (LON:SCLP) perked up 10.4% to 18.62p as broker Panmure Gordon reiterated its 'buy' rating, while Motif Bio Plc (LON:MTFB) was also benefiting from positive sentiment towards the sector – up 7.4% at 51p. While small-cap indices ...and more »
05/31/16 07:11 AMNew Analyst Ratings For Motif Bio (LON:MTFB) - Share Trading News - New Analyst Ratings For Motif Bio (LON:MTFB)Share Trading NewsA number of investment brokers have recently updated their price targets on shares of Motif Bio (LON:MTFB). According to the latest broker reports ... Motif Bio plc is a clinical-stage biopharmaceutical company. The Company is engaged in development of ...
04/20/16 06:07 AMFull Year 2015 Motif Bio PLC Earnings Release - Time Not Supplied -
04/14/16 11:48 AMHigh-level changes at Motif Bio -
03/13/16 01:51 PMHow Analysts Feel About Motif Bio PLC (LON:MTFB)? - Stock Caller - How Analysts Feel About Motif Bio PLC (LON:MTFB)?Stock CallerOut of 1 analysts covering Motif Bio Plc (LON:MTFB), 1 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Motif Bio Plc was the topic in 26 analyst reports since July 23, 2015 according to StockzIntelligence Inc. Below is a list of ...
03/11/16 01:49 PMMotif Bio (LON:MTFB) Analyst Target Prices - FTSE News - Motif Bio (LON:MTFB) Analyst Target PricesFTSE NewsMotif Bio PLC is a United Kingdom-based clinical-stage biopharmaceutical company which specializes in developing antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. The Company ...
03/09/16 01:58 PMWhat Will Happen to Motif Bio PLC Next? The Stock Just Increased A Lot - Stock Caller - What Will Happen to Motif Bio PLC Next? The Stock Just Increased A LotStock CallerThe stock of Motif Bio PLC (LON:MTFB) is a huge mover today! The stock increased 1.16% or GBX 0.5 on March 8, hitting GBX 43.5. About 130,683 shares traded hands. Motif Bio PLC (LON:MTFB) has declined 21.33% since August 6, 2015 and is ...
03/05/16 01:12 PMHow Analysts Rated Motif Bio PLC (LON:MTFB) Last Week? - Stock Caller - How Analysts Rated Motif Bio PLC (LON:MTFB) Last Week?Stock CallerOut of 1 analysts covering Motif Bio Plc (LON:MTFB), 1 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Motif Bio Plc was the topic in 26 analyst reports since July 23, 2015 according to StockzIntelligence Inc. Below is a list of ...
03/02/16 01:29 PMFirst patient dosed in iclaprim Phase 3 trials to treat skin infections - March 2, 2016 I Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces the dosing of the first patient in two Phase 3 clinical trials of its lead antibiotic candidate iclaprim ...
03/01/16 01:42 PMMotif Bio (LON:MTFB) Broker Roundup - Share Trading News - Motif Bio (LON:MTFB) Broker RoundupShare Trading NewsMotif Bio PLC is a United Kingdom-based clinical-stage biopharmaceutical company which specializes in developing antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. The Company ...
02/28/16 12:52 PMHow Analysts Feel About Motif Bio PLC (LON:MTFB)? - Clinton Financial - How Analysts Feel About Motif Bio PLC (LON:MTFB)?Clinton FinancialOut of 1 analysts covering Motif Bio Plc (LON:MTFB), 1 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Motif Bio Plc was the topic in 24 analyst reports since July 23, 2015 according to StockzIntelligence Inc. Beaufort Securities ...
02/24/16 01:28 PMWere Analysts Bearish Motif Bio PLC (LON:MTFB) This Week? - Stock Caller - Were Analysts Bearish Motif Bio PLC (LON:MTFB) This Week?Stock CallerOut of 1 analysts covering Motif Bio Plc (LON:MTFB), 0 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means NaN are positive. Motif Bio Plc was the topic in 24 analyst reports since July 23, 2015 according to StockzIntelligence Inc. Below is a list of ...
02/22/16 12:51 PMMotif Bio Plc to participate in Webcast on Combating antibiotic resistance - DirectorsTalk Interviews - DirectorsTalk InterviewsMotif Bio Plc to participate in Webcast on Combating antibiotic resistanceDirectorsTalk InterviewsMotif Bio plc (LON:MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announces that Dr. David Huang, Chief Medical Officer of Motif Bio, will participate in a BioPharma Dealmakers webcast, sponsored ...
02/22/16 12:51 PMWebcast on Combating antibiotic resistance - Motif Bio plc (AIM:MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announces that Dr. David Huang, Chief Medical Officer of Motif Bio, will participate in a BioPharma Dealmakers webcast, sponsored in ...
02/19/16 01:29 PMMotif Bio PLC Rises A lot Today, Is Now One of The Best Performer - Stock Caller - Motif Bio PLC Rises A lot Today, Is Now One of The Best PerformerStock CallerThe stock of Motif Bio PLC (LON:MTFB) is a huge mover today! The stock is down 2.44% or GBX 1 after the news, hitting GBX 40 per share. Motif Bio PLC (LON:MTFB) has declined 40.58% since July 20, 2015 and is downtrending. It has underperformed by ...
02/16/16 01:16 PMIs Selling Stock Like Motif Bio PLC After Such Decline Winning Strategy? - Sonoran Weekly Review - Is Selling Stock Like Motif Bio PLC After Such Decline Winning Strategy?Sonoran Weekly ReviewThe stock of Motif Bio PLC (LON:MTFB) is a huge mover today! The stock decreased 2.50% or GBX 1 on February 15, hitting GBX 39. About 180,080 shares traded hands or 32.20% up from the average. Motif Bio PLC (LON:MTFB) has declined 40.91% since ...
02/10/16 12:39 PMMotif Bio (LON:MTFB) Recent Analyst Updates - Risers & Fallers - Motif Bio (LON:MTFB) Recent Analyst UpdatesRisers & FallersMotif Bio PLC is a United Kingdom-based clinical-stage biopharmaceutical company which specializes in developing antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. The Company ...
02/07/16 12:43 PMWere Analysts Bullish Motif Bio PLC (LON:MTFB) This Week? - Sonoran Weekly Review - Were Analysts Bullish Motif Bio PLC (LON:MTFB) This Week?Sonoran Weekly ReviewOut of 1 analysts covering Motif Bio Plc (LON:MTFB), 1 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Motif Bio Plc was the topic in 24 analyst reports since July 23, 2015 according to StockzIntelligence Inc. Beaufort Securities ...
01/28/16 01:03 PMAppointments of US corporate finance adviser and auditor - FierceBiotech - Appointments of US corporate finance adviser and auditorFierceBiotechMotif Bio plc (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces today the appointment of U.S. healthcare investment bank MTS Health Partners (MTS) to advise on its future financing options ...
01/25/16 12:40 PMNorthland Capital Kept Motif Bio Plc (LON:MTFB) As “Buy”; Has Price Objective Of GBX 114.00 - OctaFinance.com - DirectorsTalk InterviewsNorthland Capital Kept Motif Bio Plc (LON:MTFB) As “Buy”; Has Price Objective Of GBX 114.00OctaFinance.comInvestment analysts at Northland Capital have GBX 114.00 target price on Motif Bio Plc (LON:MTFB). Northland Capital's target price gives a potential upside of 210.20 % from the company's current stock price. The rating was released in an analyst ...Motif Bio PLC (MTFB) Stock Rating Reaffirmed by Northland SecuritiesIRA Market ReportMotif Bio PLC Appointments of U.S. finance adviser and auditorDirectorsTalk Interviewsall 13 news articles »
01/25/16 12:40 PMMOTIF BIO PLC ( MTFB ) - Motif Bio plc (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces today the appointment of U.S. healthcare investment bank MTS Health Partners (MTS) to advise on its future financing options ...
About Motif Bio PLC

Motif Bio PLC logoMotif Bio plc is a clinical-stage biopharmaceutical company. The Company is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It operates in the development and commercialization of pharmaceutical formulations segment. The Company is focused on development of its product, Iclaprim, for the treatment of the bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumonia (MDRSP). Its Iclaprim exhibits potent activity against Gram-positive clinical isolates of various genera of staphylococci. It focuses on building a portfolio of antibiotics by licensing drug candidates from organizations specializing in antibacterial research, and is pursuing programs in various stages of development.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: LON
  • Symbol: MTFB
  • CUSIP:
Key Metrics:
  • Previous Close: $0.66
  • 50 Day Moving Average: $47.19
  • 200 Day Moving Average: $43.91
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $54.30M
  • Current Quarter EPS Consensus Estimate: $-26.76 EPS
Additional Links:

            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha